Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Piramal Pharma Ltd.
Change Company   
BSE Code 543635
ISIN Demat INE0DK501011
Book Value 56.48
NSE Code PPLPHARMA
Dividend Yield % 0.07
Market Cap 266913.02
P/E 37.11
EPS 5.41
Face Value 10  
22-Aug-2025 Piramal Pharma Solutions, NewAmsterdam Pharma ope...
31-Jul-2025 Piramal Pharma informs about transcript of confer...
29-Jul-2025 Piramal Pharma reports consolidated net loss of R...
10-Jul-2025 Piramal Pharma informs about updates
02-Jun-2025 USFDA concludes GMP inspection at Piramal Pharma’...
02-Jun-2025 Piramal Pharma informs about disclosure
21-May-2025 Piramal Pharma informs about outcome of allotment...
15-May-2025 Piramal Pharma reports 51.57% rise in Q4 consolid...
12-May-2025 Piramal Pharma receives EIR from USFDA for Turbhe...
12-May-2025 Piramal Pharma gains on receiving EIR from USFDA ...
29-Apr-2025 Piramal Pharma informs about conference call
24-Apr-2025 Piramal Pharma’s arm inks pact with PPL Pharma
10-Apr-2025 Piramal Finance partners with ICICI Bank
03-Apr-2025 Piramal Pharma shines on commencing commercial pr...
02-Apr-2025 Piramal Pharma commences commercial production of...
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.